Filgrastim in the treatment of infected diabetic foot ulcers: retrospective cost analysis of a phase II randomised clinical trial

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The authors concluded that the overall clinical benefit with the use of G-CSF resulted in cost savings. Savings were accounted for by the avoidance of more costly treatment interventions including longer hospital stay and more aggressive treatment (angioplasty, vascular reconstruction and amputation).